Docket Number:10A-1000831
Inventor:Wu H. C., Tung K. H.
IP Status:US 8,969,530, TW I 485158
Abstract:
We generated a new monoclonal antibody which specifically bound to various cancer cells and blood vessels through its recognition of CHC. Expression levels of CHC are directly related to tumor progression with high expressions of CHC correlated to a higher malignant stages and poor prognosis. CHC mAb, Pa65-2, or CHC shRNA disrupted the protein stability of HIF-1α decreasing its nuclear translocation and, thus, disrupting VEGF transcription. The Pa65-2 can be used to inhibit tumor angiogenesis and growth. This mAb also can be used to develop diagnostic reagents, targeting drug delivery systems and imaging for solid tumor.
Fields of Application:
- Development of therapeutic antibody for treatment of solid tumor and angiogenic-related diseases.
- Development of diagnostic or reagents for cancer
- Development of targeting drug delivery systems for cancer therapy.
- Development of targeting imaging for cancer.
Advantages when compared to the existing technologies:
The present invention relates to an anti-CHC monoclonal antibody for inhibition of tumor angiogenesis and growth and application thereof. The mAb specifically binds to various cancer cells and tumor blood vessels but not normal cells. Animal studies have indicated that the antibody treatment inhibited pancreatic tumor growth. This mAb can be used to develop diagnostic reagents, targeting drug delivery systems and imaging.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
